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Abstract: Cardiogenic shock is a high-mortality condition caused, mostly, by ST-elevation myocardial infarction. When 
the adequate therapy is implemented in a timely fashion, recovery can be achieved. Treatment is based on intensive 
care measures, vasoactive drugs, early revascularization and the use of assist circulatory devices. In this review, the 
authors aim to discuss the available evidence on the use of intra-aortic balloon pump (IABP) in this clinical setting. 
Keywords: Intra-aortic balloon pump, Counterpulsation, Myocardial infarction, Cardiogenic shock, Mortality, 
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INTRODUCTION 
Cardiogenic shock (CS) is a condition with a high 
mortality rate - around 50% [1] -, defined by a state of 
tissue malperfusion caused by heart failure (HF) and 
complicates up to 8% of cases of ST-elevation 
myocardial infarction (STEMI) [2,3]. Although a critical 
condition, it can be reversed if the proper set of 
therapies is instituted in time and the correct 
identification of in-risk patients is made. Therefore, 
some risk factors related to the development of CS in 
patients with an acute myocardial infarction (AMI) must 
be emphasized: older age, anterior MI, hypertension, 
diabetes, multivessel coronary heart disease, prior MI 
or HF and left bundle-branch block [4]. 
Treatment of CS is based, mainly, on coronary 
reperfusion; more specifically, on early 
revascularization (percutaneous coronary intervention 
– PCI – or coronary artery bypass graft – CABG). The 
survival benefit of non-delayed revascularization was 
clearly demonstrated in the randomized “Should We 
Emergently Revascularize Occluded Coronaries for 
Cardiogenic Shock” (SHOCK) trial, with an absolute 
increase of 13% in 1-year survival compared to those 
assigned to initial clinical stabilization [5, 6]. 
However, mechanical circulatory support is, in a 
large proportion of cases, an important adjunctive  
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therapy. In such cases, the most commonly used 
device is the intra-aortic balloon pump (IABP). There 
are evidence both demonstrating its benefits as well as 
showing no advantage in the setting of CS. [7-17]. 
INTRA-AORTIC BALLOON PUMP 
 Intra-aortic balloon pump is the most commonly 
used mechanical support device to improve circulatory 
hemodynamics in cardiogenic shock. Based on the 
principle of counterpulsation, it was first clinically 
applied in the late 1960s, by Kantrowitz et al. [18]. In 
the early 1980s [19] its use became widespread since 
the development of a percutaneous approach for 
insertion  
It is composed of a flexible catheter with a lumen 
that permits pressure monitoring, and a second one 
that allows the periodic in- and outflow of helium gas to 
a polyethylene balloon; also a console which contains 
the helium transfer system and an electronic control for 
the inflation-deflation cycle. 
The catheter is inserted through the common 
femoral artery and advanced - either at the bedside or 
under fluoroscopic guidance in the cath lab - so the 
distal tip is positioned in the proximal descending aorta 
- 1-2 cm below the emergence of the left subclavian 
artery - and the proximal portion is placed above the 
renal arteries. The console controls the pumping using 
input from the aortic pressure and/or the 
electrocardiogram. Inflation occurs just after aortic 
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valve closure, and deflation must happen immediately 
before aortic valve opening  
 
Figure 1: Cardiac cycle and normal timing of IABP inflation - 
dotted line). 
The hemodynamic effects depend on the 
appropriate balloon size and timing of the inflation-
deflation cycle. When properly set, the use of IABP 
results in: decrease in systolic pressure (during balloon 
deflation, consequence of a reduction of left ventricle 
after load); increase in diastolic pressure (during 
balloon inflation, which raises coronary blood flow); 
reduction of heart rate (in nearly 10-20%); and 
elevation of cardiac output [20]. The net result is an 
improvement in cardiac energy balance, with a 
decrement in myocardial oxygen demand and 
augmentation of oxygen supply [21].  
According to the 2013 American College of 
Cardiology/American Heart Association (ACC/AHA) 
guidelines for the management of STEMI, the use of 
IABP can be useful for those with CS in this setting 
who do not quickly stabilize with pharmacological 
therapy [22], receiving a Class II a recommendation. 
Noteworthy is the fact that IABP use in CS was 
downgraded in relation to the earlier edition of those 
guidelines [23], where it used to receive a Class IB 
recommendation. 
Data regarding complications associated with IABP 
are difficult to be summarized as a general topic 
because of the heterogeneity of studies - not only 
regarding study population, but also in the definitions of 
such complications. However, it is known that vascular 
complications - arterial laceration with need of surgical 
repair, limb ischemia (with eventual amputation) and 
major bleeding - are the most common IABP-related 
complications. Embolization, infection and IABP rupture 
may also occur. In the Benchmark Registry, the 
authors evaluated 22,663 consecutive patients in 
whom an IABP was inserted at 250 centers worldwide 
from 1996 to 2001, and Stone et al. [24] analyzed the 
5,495 of those subjects who had an MI. In their study, 
one or more complications of IABP use occurred in 
8.1% of patients, although major complications (severe 
limb ischemia - requiring surgical therapy -, severe 
bleeding - need of blood transfusion/surgical 
intervention or associated with hemodynamic 
compromise -, balloon leak or death directly due to 
IABP insertion or failure) occurred in only 2.7% of 
cases. Regarding those patients in whom IABP was 
used for CS, the rate of major complications was 2.9%. 
Ferguson et al. [25], in a previous publication of the 
same Registry, performed a multivariate logistic 
regression analysis to identify independent predictors 
of a major IABP-related complication. The results 
showed that female gender (OR 1.968; CI 1.557 - 
2.487), peripheral vascular disease (OR 1.737; CI 
1.414 - 2.134), small body surface area (BSA; <1.65 
m2) (OR 1.453; CI 1.095 - 1.926) and higher age (≧75 
years) (OR 1.289; CI 1.048 - 1.585) were significantly 
related to an increased risk of such events. 
INTRA-AORTIC BALLOON PUMP IN CARDIOGENIC 
SHOCK 
Data regarding the use of IABP in patients with 
cardiogenic shock complicating an MI are controversial 
and the majority of positive results come from 
observational non-controlled studies. This was thought 
to be the reason for the low (<40%) use of IABP in this 
clinical scenario [26]. 
O`Rourke et al. [7], in 1981, studied the value of 
IABP in patients with early MI complicated by acute 
heart failure. Thirty patients were randomized to IABP 
or standard therapy, and no significant difference 
between groups was seen in infarct size, morbidity or 
mortality during a mean follow-up of 15 months.  
In the analysis of 200 consecutive patients at Duke 
University with MI-related CS, between 1987 and 1988, 
99 subjects used IABP [8]; the in-hospital mortality was 
lower (48% x 57%; p=0.23) in those who used IABP 
than in those who did not. Stomel et al. [9] examined 
64 consecutive patients with MI and CS dividing the 
patients in three groups: thrombolytic therapy, IABP 
and combined thrombolysis plus IABP. The groups 
were similar in regard to age, sex, medical history, 
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hemodynamic data and extent of coronary artery 
disease. Survival was improved in patients treated with 
combined thrombolytic therapy and IABP support (23% 
x 28% x 68%, respectively; p=0.0049). 
More than 40,000 subjects were enrolled in the 
“Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Arteries” (GUSTO 
I) trial, and all were eligible for thrombolytic therapy. A 
small percentage (7%; n=2,972) developed CS after 
STEMI [10]. Therapy included the use of IABP in 734 
patients. The results showed that early insertion of 
IABP in these patients was related to a non-significant 
decrease in mortality compared to those cases in which 
it was used with delay or not inserted (47% x 60%; 
p=0.06). In the same year, Hochman et al. reported 
data from the SHOCK Registry [11] analyzing 251 
patients from 19 American and Belgian centers where 
both thrombolysis and mechanical revascularization 
were used. Patients in whom IABP was used were 
significantly younger, more often underwent coronary 
angiography and had no benefit in adjusted mortality 
compared to those in whom IABP was not used 
(p=0.66). This lack of benefit in mortality also occurred 
in those who underwent coronary angioplasty (62% 
with IABP x 54% without IABP; p=0.743).  
A later analysis of 856 subjects from 36 participating 
centers in the SHOCK Trial Registry showed lower 
mortality rates in those who used IABP compared to 
those who did not (50% x 72%; p< 0.0001), and in the 
group treated with the combination of thrombolytic plus 
IABP compared to the one who did not receive nor 
thrombolytic nor IABP (47% x 77%; p< 0.0001) [12]. 
Similarly, in a retrospective analysis of data from the 
SHOCK trial, French et al. [13] observed a reduction in 
1-year mortality, yet not statistically significant, in those 
patients assigned to initial medical stabilization who 
received the combination of thrombolysis and IABP 
compared to those who did not use IABP (41% x 64%; 
p=0.07). 
One crucial aspect when performing invasive 
procedures is the level of expertise presented by 
hospitals and their staff. This point was addressed by 
Chen et al. [14] using data from over 12,000 patients 
enrolled in the National Registry of Myocardial 
Infarction (NRMI) in the mid 1990`s. In their paper, the 
authors demonstrated that patients treated in hospitals 
with a high IABP volume had lower mortality (OR 0.71; 
95% CI 0.56-0.90) regardless of other factors. 
In the TACTICS trial [15], 57 subjects were 
randomized to fibrinolytic therapy alone or the 
combination of fibrinolysis plus IABP. The primary 
endpoint was all-cause mortality in 6 months and the 
results showed no significant difference between 
groups (34% for combination x 43% for fibrinolysis 
alone; p=0.23) but a trend toward significant benefit in 
this same outcome when combination therapy was 
used in those with more severe conditions (Killip III/IV) 
- 39% x 80% 6-month mortality, respectively; p=0.05). 
In 2009, Sjauw et al. [16] performed two different 
analyses with previous studies in patients with CS 
following STEMI: the first one was restricted to data 
from randomized trials, in a total of seven trials and 
1,009 patients; the other included nine cohorts with 
more than 10,000 subjects. The results from the first 
analysis showed no advantage of IABP in 1-month 
survival - but higher rates of stroke and bleeding. In the 
second analysis, the use of IABP in patients treated 
with thrombolysis was related to an 18% lower mortality 
in 30 days (95% CI 16-20; p<0.0001); however, in 
those treated with primary PCI, IABP was associated 
with a 6% increase in the same endpoint (95% 3-10; 
p<0.0008). The authors concluded the article 
challenging the available guideline recommendations at 
that time. 
More recently, the IABP-SHOCK II trial was 
published with the aim to answer the question if IABP 
was capable of reduce mortality in patients with CS 
following MI for whom early revascularization was 
planned [17]. It was a multicenter, open-label, 
randomized study where 600 patients were randomly 
assigned (1:1 ratio) to IABP or non-IABP and were 
expected to be treated with early revascularization 
(primary PCI with treatment of the target lesion only, 
PCI of the target lesion plus additional immediate or 
staged PCI of nontarget lesions, or CABG at the 
discretion of the operator). There was no difference in 
the primary outcome (30-day mortality) among groups 
(39.7% IABP x 41.3% non-IABP; RR with IABP 0.96, 
95% CI 0.79-1.17; p=0.69). In terms of safety, there 
was no significant difference between groups with 
respect to the rates of stroke, bleeding, sepsis or 
vascular complications requiring intervention. 
CONCLUSIONS 
When faced with such condition, one must keep in 
mind the considerable severity inherent to it, where 
pump failure is the primary derangement but other 
parts of the circulatory system play a role with 
inadequate compensation or additional defects [27]. 
Another point to be remembered is that the cornerstone 
in the treatment of such cases is early 
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revascularization; the use of assist circulatory devices 
is an adjunctive therapy - and nothing more.  
Compared to other devices, e.g. TandemHeart and 
Impella, IABP does not need a surgeon to be inserted. 
It can be inserted either under fluoroscopic guidance or 
at the bedside by the interventional cardiologist, clinical 
cardiologist or intensive care physician. Studies in 
which patients were randomly assigned to treatment 
with IABP or TandemHeart showed that latter was 
related to an increase risk – significantly [28] and non-
significantly [29] – of severe bleeding. When it comes 
to the comparison between Impella and IABP, Seyfath 
et al. [30] found similar results. Noteworthy is the fact 
that both TandemHeart and Impella had better 
hemodynamic data than IABP, although this was not 
translated into significantly lower mortality.  
Considering the high costs involved in the treatment 
of patients with myocardial infarction complicated by 
cardiogenic shock, and the net results demonstrated so 
far by newer, more expensive devices, IABP might still 
be the most cost-effective option in this clinical setting.  
Although the recent downgrade in the 
recommendation for its use in this setting, IABP may be 
the assist circulatory device with the best combination 
of ease of insertion and handling, lower complication 
rates, potential benefits in terms of hemodynamics and 
outcomes and cost-effectiveness. 
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